文献速递肾移植

兔抗胸腺细胞球蛋白与阿仑单抗及巴利昔单抗在循环死亡后供肾移植中的比较

Thymoglobulin Versus Alemtuzumab Versus Basiliximab Kidney Transplantation From Donors After Circulatory Death.
PubMed 文献 · Kidney Int Rep · 2022-01-14

本研究将3C研究中274例循环死亡后供肾(DCD)移植患者数据与单中心140例接受兔抗胸腺细胞球蛋白诱导的DCD患者数据合并,共414例比较三种诱导方案。兔抗胸腺细胞球蛋白组6个月和2年删失肾存活率分别为98.6%和97.9%,阿仑单抗组为95.5%和94.8%,巴利昔单抗组为95.7%和94.3%;2年急性排斥率巴利昔单抗组17%、兔抗胸腺细胞球蛋白组4.3%、阿仑单抗组6%(P < 0.001)。结论认为在DCD移植中兔抗胸腺细胞球蛋白诱导可能在患者生存方面优于阿仑单抗,在急性排斥方面与阿仑单抗优于巴利昔单抗的优势相同。

要点

  • 2年急性排斥率:巴利昔单抗组17%、兔抗胸腺细胞球蛋白组4.3%、阿仑单抗组6%(P < 0.001)。
  • 2年总体肾存活率:兔抗胸腺细胞球蛋白组95% vs 阿仑单抗组88%(未校正P = 0.038,校正HR 2.4,95%CI 0.99-5.9)。
  • 2年患者生存率:阿仑单抗组91.8% vs 兔抗胸腺细胞球蛋白组97.1%(P = 0.052,HR 2.90,95%CI 0.93-9.2)。

核心结论

  • 在DCD移植中,兔抗胸腺细胞球蛋白诱导可能在患者生存方面优于阿仑单抗,在急性排斥方面与阿仑单抗优于巴利昔单抗的优势相同。
  • 维持性免疫抑制方案的差异可能 contribute to 所发现的差异。

研究设计与样本

  • 将3C研究中274例DCD患者数据与单中心140例接受兔抗胸腺细胞球蛋白诱导且入组标准与3C相同的DCD患者数据合并,共414例接受三种诱导方案。

主要发现

  • 6个月删失肾存活率:兔抗胸腺细胞球蛋白组98.6%,阿仑单抗组95.5%(P = 0.08),巴利昔单抗组95.7%(P = 0.09)。
  • 2年删失肾存活率:兔抗胸腺细胞球蛋白组97.9% vs 阿仑单抗组94.8%(P = 0.13,HR 2.8,95%CI 0.7-10.9)vs 巴利昔单抗组94.3%(P = 0.06,HR 3.5,95%CI 0.9-13.6)。
  • 2年总体肾存活率:兔抗胸腺细胞球蛋白组95% vs 阿仑单抗组88%(未校正P = 0.038,校正HR 2.4,95%CI 0.99-5.9),巴利昔单抗组91.4%(P = 0.21)。
  • 2年患者生存率:阿仑单抗组91.8% vs 兔抗胸腺细胞球蛋白组97.1%(P = 0.052,HR 2.90,95%CI 0.93-9.2),数值上阿仑单抗组较低。
  • 急性排斥率:巴利昔单抗组17%,兔抗胸腺细胞球蛋白组4.3%,阿仑单抗组6%(P < 0.001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The Campath, Calcineurin inhibitor (CNI) reduction, and Chronic allograft nephropathy (3C), a study comparing alemtuzumab versus basiliximab induction immunosuppression in kidney transplants, has found lower acute rejection rate with alemtuzumab but same graft survival. The aim of the current study is to evaluate the effect of induction immunosuppression (thymoglobulin, alemtuzumab, basiliximab) on the outcome of kidneys of donors after circulatory death (DCD). METHODS: Data of the 274 DCD patients of the 3C obtained from the sponsor were compounded with the 140 DCD patients who received thymoglobulin in a single center with the same entry criteria as the 3C, giving 414 patients on 3 induction regimes. RESULTS: There were more male donors (P < 0.05) and human leukocyte antigen and DR mismatched patients in the thymoglobulin group (P < 0.001). Death-censored graft survival at 6 months was 98.6% in the thymoglobulin, 95.5% in the alemtuzumab (P = 0.08), and 95.7% in the basiliximab group (P = 0.09) and at 2 years 97.9% versus 94.8% (P = 0.13, hazard ratio [HR] 2.8, 95% CI 0.7-10.9) versus 94.3% (P = 0.06, HR 3.5, 95% CI 0.9-13.6), respectively.The 2-year overall graft survival was 95% in the thymoglobulin versus 88% in the alemtuzumab (unadjusted P = 0.038, adjusted HR 2.4, 95% CI 0.99-5.9) and 91.4% in the basiliximab group (P = 0.21). The 2-year patient survival was numerically less in the alemtuzumab compared with the thymoglobulin group (91.8% vs. 97.1%, P = 0.052, HR 2.90, 95% CI 0.93-9.2). Acute rejection was 17% in the basiliximab, 4.3% in the thymoglobulin, and 6% in the alemtuzumab group (P < 0.001). CONCLUSION: In DCD transplants, thymoglobulin induction may provide advantage over alemtuzumab in patient survival and the same advantage as alemtuzumab over basiliximab in terms of acute rejection. Differing maintenance immunosuppression may contribute to the difference found.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Asderakis A, Sabah TK, Watkins WJ, et al. Thymoglobulin Versus Alemtuzumab Versus Basiliximab Kidney Transplantation From Donors After Circulatory Death. Kidney Int Rep. 2022. PMID: 35497810. doi:10.1016/j.ekir.2022.01.1042

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。